Ihsan Gursel

List of Publications by Year
in descending order

70 papers	8,926 citations	117453 34 h-index	98622 67 g-index
70 all docs	70 docs citations	70 times ranked	13476 citing authors

#	Article	IF	Citations
1	Development and preclinical evaluation of virusâ€like particle vaccine against COVIDâ€19 infection. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 258-270.	2.7	27
2	Low Density Granulocytes and Dysregulated Neutrophils Driving Autoinflammatory Manifestations in NEMO Deficiency. Journal of Clinical Immunology, 2022, 42, 582-596.	2.0	3
3	3D-MSCs A151 ODN-loaded exosomes are immunomodulatory and reveal a proteomic cargo that sustains wound resolution. Journal of Advanced Research, 2022, 41, 113-128.	4.4	17
4	Effects of Obesity on Airway and Systemic Inflammation in Asthmatic Children. International Archives of Allergy and Immunology, 2021, 182, 679-689.	0.9	13
5	Rational Vaccine Design in Times of Emerging Diseases: The Critical Choices of Immunological Correlates of Protection, Vaccine Antigen and Immunomodulation. Pharmaceutics, 2021, 13, 501.	2.0	15
6	The role of bcsE gene in the pathogenicity of Salmonella. Pathogens and Disease, 2021, 79, .	0.8	4
7	Circulating extracellular vesicles of steroid sensitive nephrotic syndrome patients have higher RAC1 and induce recapitulation of nephrotic syndrome phenotype in podocytes. American Journal of Physiology - Renal Physiology, 2021, 321, F659-F673.	1.3	4
8	TLR ligand loaded exosome mediated immunotherapy of established mammary Tumor in mice. Immunology Letters, 2021, 239, 32-41.	1.1	13
9	A suppressive oligodeoxynucleotide expressing TTAGGG motifs modulates cellular energetics through the mTOR signaling pathway. International Immunology, 2020, 32, 39-48.	1.8	10
10	Human Gut Commensal Membrane Vesicles Modulate Inflammation by Generating M2-like Macrophages and Myeloid-Derived Suppressor Cells. Journal of Immunology, 2020, 205, 2707-2718.	0.4	31
11	Dual-adjuvant effect of pH-sensitive liposomes loaded with STING and TLR9 agonists regress tumor development by enhancing Th1 immune response. Journal of Controlled Release, 2020, 328, 587-595.	4.8	33
12	Mesenchymal stem cell derived extracellular vesicles: promising immunomodulators against autoimmune, autoinflammatory disorders and SARS-CoV-2 infection. Turkish Journal of Biology, 2020, 44, 273-282.	2.1	24
13	Modulation of immune responses using adjuvants to facilitate therapeutic vaccination. Immunological Reviews, 2020, 296, 169-190.	2.8	56
14	Is global BCG vaccinationâ€induced trained immunity relevant to the progression of SARSâ€CoVâ€2 pandemic?. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1815-1819.	2.7	118
15	Type I IFNâ€“related NETosis in ataxia telangiectasia and Artemis deficiency. Journal of Allergy and Clinical Immunology, 2018, 142, 246-257.	1.5	47
16	Encapsulation of two different TLR ligands into liposomes confer protective immunity and prevent tumor development. Journal of Controlled Release, 2017, 247, 134-144.	4.8	45
17	Circulating LL37 targets plasma extracellular vesicles to immune cells and intensifies BehÃ§et's disease severity. Journal of Extracellular Vesicles, 2017, 6, 1284449.	5.5	11
18	Impaired toll like receptor-7 and 9 induced immune activation in chronic spinal cord injured patients contributes to immune dysfunction. PLoS ONE, 2017, 12, e0171003.	1.1	9

#	Article	IF	Citations
19	Efficient production and enhanced tumor delivery of engineered extracellular vesicles. Biomaterials, 2016, 105, 195-205.	5.7	286
20	Development of CpG ODN Based Vaccine Adjuvant Formulations. Methods in Molecular Biology, 2016, 1404, 289-298.	0.4	14
21	Structure, mechanism and therapeutic utility of immunosuppressive oligonucleotides. Pharmacological Research, 2016, 105, 216-225.	3.1	26
22	Evidence-Based Clinical Use of Nanoscale Extracellular Vesicles in Nanomedicine. ACS Nano, 2016, 10, 3886-3899.	7.3	397
23	Intestinal Microbiota in Patients with Spinal Cord Injury. PLoS ONE, 2016, 11, e0145878.	1.1	124
24	Biological properties of extracellular vesicles and their physiological functions. Journal of Extracellular Vesicles, 2015, 4, 27066.	5.5	3,973
25	Enhanced immunostimulatory activity of cyclic dinucleotides on mouse cells when complexed with a cellâ€penetrating peptide or combined with CpG. European Journal of Immunology, 2015, 45, 1170-1179.	1.6	31
26	CpG ODN Nanorings Induce IFNÎ± from Plasmacytoid Dendritic Cells and Demonstrate Potent Vaccine Adjuvant Activity. Science Translational Medicine, 2014, 6, 235ra61.	5.8	81
27	Forging a potent vaccine adjuvant: CpG ODN/cationic peptide nanorings. OncoImmunology, 2014, 3, e950166.	2.1	8
28	Immunomodulatory function and in vivo properties of Pediococcus pentosaceus OZF, a promising probiotic strain. Annals of Microbiology, 2013, 63, 1311-1318.	1.1	16
29	Suppression of <scp>B</scp>â€cell activation and <scp>I</scp>g<scp>E</scp>,<scp> I</scp>g<scp>A</scp>,<scp> I</scp>g<scp>G</scp>1 and <scp>I</scp>g<scp>G</scp>4 production by mammalian telomeric oligonucleotides. Allergy: European Journal of Allergy and Clinical Immunology, 2013, 68, 593-603.	2.7	27
30	Plasmacytoid Dendritic Cell Response to CpG ODN Correlates with CXCL16 Expression and Is Inhibited by ox-LDL. Mediators of Inflammation, 2013, 2013, 1-7.	1.4	2
31	Immunogenicity and protective efficacy of the recombinant Pasteurella lipoprotein E and outer membrane protein H from Pasteurella multocida A:3 in mice. Research in Veterinary Science, 2012, 93, 1261-1265.	0.9	23
32	Immobilization of laccase on itaconic acid grafted and Cu(II) ion chelated chitosan membrane for bioremediation of hazardous materials. Journal of Chemical Technology and Biotechnology, 2012, 87, 530-539.	1.6	53
33	The effects of an insertion in the 5â€²UTR of the AMCase on gene expression and pulmonary functions. Respiratory Medicine, 2011, 105, 1160-1169.	1.3	7
34	Immunostimulatory activity of polysaccharideâ€“poly(I:C) nanoparticles. Biomaterials, 2011, 32, 4275-4282.	5.7	22
35	Differential immune activation following encapsulation of immunostimulatory CpG oligodeoxynucleotide in nanoliposomes. Biomaterials, 2011, 32, 1715-1723.	5.7	43
36	Mammalian Telomeric DNA Suppresses Endotoxin-induced Uveitis*. Journal of Biological Chemistry, 2010, 285, 28806-28811.	1.6	7

#	Article	IF	Citations
37	Biosorption of phenol and 2-chlorophenol by Funalia trogii pellets. Bioresource Technology, 2009, 100, 2685-2691.	4.8	97
38	Parametrically coupled multiharmonic force imaging. Applied Physics Letters, 2008, 92, .	1.5	4
39	CpG-mediated changes in gene expression in murine spleen cells identified by microarray analysis. Molecular Immunology, 2007, 44, 1095-1104.	1.0	30
40	CXCL16 Influences the Nature and Specificity of CpG-Induced Immune Activation. Journal of Immunology, 2006, 177, 1575-1580.	0.4	68
41	Therapeutic Potential of Oligonucleotides Expressing Immunosuppressive TTAGGG Motifs. Annals of the New York Academy of Sciences, 2005, 1058, 87-95.	1.8	27
42	Suppressive Oligodeoxynucleotides Protect Mice from Lethal Endotoxic Shock. Journal of Immunology, 2005, 174, 4579-4583.	0.4	84
43	CpG Oligodeoxynucleotides Adsorbed onto Polylactide-Co-Glycolide Microparticles Improve the Immunogenicity and Protective Activity of the Licensed Anthrax Vaccine. Infection and Immunity, 2005, 73, 828-833.	1.0	117
44	Use of CpG oligodeoxynucleotides as immune adjuvants. Immunological Reviews, 2004, 199, 201-216.	2.8	270
45	Signal transduction pathways mediated by the interaction of CpG DNA with Toll-like receptor 9. Seminars in Immunology, 2004, 16, 17-22.	2.7	165
46	Immunotherapeutic utility of stimulatory and suppressive oligodeoxynucleotides. Current Opinion in Molecular Therapeutics, 2004, 6, 166-74.	2.8	30
47	Regulation of CpG-Induced Immune Activation by Suppressive Oligodeoxynucleotides. Annals of the New York Academy of Sciences, 2003, 1002, 112-123.	1.8	33
48	Repetitive Elements in Mammalian Telomeres Suppress Bacterial DNA-Induced Immune Activation. Journal of Immunology, 2003, 171, 1393-1400.	0.4	211
49	Reduction of Surgery-Induced Peritoneal Adhesions by Continuous Release of Streptokinase from a Drug Delivery System. European Surgical Research, 2003, 35, 46-49.	0.6	19
50	Antitumor therapy with bacterial DNA and toxin: complete regression of established tumor induced by liposomal CpG oligodeoxynucleotides plus interleukin-13 cytotoxin. Clinical Cancer Research, 2003, 9, 6516-22.	3.2	27
51	Effect of Suppressive DNA on CpG-Induced Immune Activation. Journal of Immunology, 2002, 169, 5590-5594.	0.4	101
52	Potential Role of Phosphatidylinositol 3 Kinase, rather than DNA-dependent Protein Kinase, in CpG DNAâ€“induced Immune Activation. Journal of Experimental Medicine, 2002, 196, 269-274.	4.2	129
53	In vitro antibiotic release from poly(3-hydroxybutyrate-co-3-hydroxyvalerate) rods. Journal of Microencapsulation, 2002, 19, 153-164.	1.2	80
54	Chondroitin sulfateâ€“coated polyhydroxyethyl methacrylate membrane prevents adhesion in full-thickness tendon tears of rabbits. Journal of Hand Surgery, 2002, 27, 293-306.	0.7	46

#	Article	IF	Citations
55	Reduction of CpG-induced arthritis by suppressive oligodeoxynucleotides. Arthritis and Rheumatism, 2002, 46, 2219-2224.	6.7	81
56	CpG DNA: recognition by and activation of monocytes. Microbes and Infection, 2002, 4, 897-901.	1.0	64
57	Differential and competitive activation of human immune cells by distinct classes of CpG oligodeoxynucleotide. Journal of Leukocyte Biology, 2002, 71, 813-20.	1.5	127
58	Biodegradable polyhydroxyalkanoate implants for osteomyelitis therapy: in vitro antibiotic release. Journal of Biomaterials Science, Polymer Edition, 2001, 12, 195-207.	1.9	98
59	In vivo response to biodegradable controlled antibiotic release systems. Journal of Biomedical Materials Research Part B, 2001, 55, 217-228.	3.0	54
60	Sterically Stabilized Cationic Liposomes Improve the Uptake and Immunostimulatory Activity of CpG Oligonucleotides. Journal of Immunology, 2001, 167, 3324-3328.	0.4	180
61	Cutting Edge: Role of Toll-Like Receptor 9 in CpG DNA-Induced Activation of Human Cells. Journal of Immunology, 2001, 167, 3555-3558.	0.4	529
62	In vivo application of biodegradable controlled antibiotic release systems for the treatment of implant-related osteomyelitis. Biomaterials, 2000, 22, 73-80.	5.7	135
63	Activation of the innate immune system by CpG oligodeoxynucleotides: immunoprotective activity and safety. Seminars in Immunopathology, 2000, 22, 173-83.	4.0	23
64	Antibiotic release from biodegradable PHBV microparticles. Journal of Controlled Release, 1999, 59, 207-217.	4.8	189
65	Sulbactam-cefoperazone polyhydroxybutyrate-co- hydroxyvalerate (PHBV) local antibiotic delivery system:In vivo effectiveness and biocompatibility in the treatment of implant-related experimental osteomyelitis. , 1999, 46, 494-503.		96
66	Synthesis and mechanical properties of interpenetrating networks of polyhydroxybutyrate-co-hydroxyvalerate and polyhydroxyethyl methacrylate. Biomaterials, 1998, 19, 1137-1143.	5.7	57
67	Antibiotic Release from Biodegradable PHBV Microparticles. , 1998, , 89-96.		2
68	Liposomes as immunological adjuvants and vaccine carriers. Journal of Controlled Release, 1996, 41, 49-56.	4.8	73
69	Properties and drug release behaviour of poly(3-hydroxybutyric acid) and various poly(3-hydroxybutyrate-hydroxyvalerate) copolymer microcapsules. Journal of Microencapsulation, 1995, 12, 185-193.	1.2	60
70	ADMINISTRATION OF BONE MARROW DERIVED MESENCHYMAL STEM CELLS MODULATE TLR EXPRESSION DURING LIVER REGENERATION. Trakya University Journal of Natural Sciences, 0, 20, 1-10.	0.4	0